Regorafenib Combination Therapy in Advanced Hepatocellular Carcinoma: With or Without Transarterial Chemoembolization.

IF 2.5 3区医学 Q3 ONCOLOGY

Oncology Pub Date : 2024-11-27 DOI:10.1159/000542775

Lei Cao, Xiangyu Lu, Haoqing Chen, Xiang Yu, Jinze Li, Yi Peng, Lu Gu, Ji Feng, Ping Xie, Yaben Liu

{"title":"Regorafenib Combination Therapy in Advanced Hepatocellular Carcinoma: With or Without Transarterial Chemoembolization.","authors":"Lei Cao, Xiangyu Lu, Haoqing Chen, Xiang Yu, Jinze Li, Yi Peng, Lu Gu, Ji Feng, Ping Xie, Yaben Liu","doi":"10.1159/000542775","DOIUrl":null,"url":null,"abstract":"Introduction: The effectiveness and tolerability of triple therapy, which combines regorafenib, a programmed death 1 (PD-1) inhibitor, and transarterial chemoembolization (TACE), were compared to dual therapy consisting of regorafenib and a PD-1 inhibitor in patients with advanced hepatocellular carcinoma (HCC).Methods: A retrospective analysis was conducted on patients with advanced HCC who underwent second-line therapy from March 2019 to June 2022 at multiple centers. Patients were stratified into two groups: dual therapy (comprising regorafenib and a PD-1 inhibitor) and triple therapy (consisting of regorafenib, a PD-1 inhibitor, and TACE). Propensity score matching (PSM) was used to control for potential confounding variables.Results: After PSM, 112 eligible patients were included, with 56 in the triple therapy group and 56 in the dual therapy group. Median overall survival (OS) was significantly longer in the triple therapy group (15.4 vs. 8.9 months, p < 0.001), as was median progression-free survival (PFS) (6.8 vs. 3.3 months, p < 0.001). The objective response rate (ORR) (37.5% vs. 5.4%, p < 0.001) and disease control rate (DCR) (73.2% vs. 44.6%, p = 0.002) were significantly higher in the triple therapy group compared to the dual therapy group. The incidence and severity of adverse events were similar between the two groups.Conclusion: Triple therapy demonstrated superior survival benefits compared to dual therapy in patients with advanced HCC. Additionally, the safety profiles of the two treatment regimens were comparable.","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-22"},"PeriodicalIF":2.5000,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000542775","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The effectiveness and tolerability of triple therapy, which combines regorafenib, a programmed death 1 (PD-1) inhibitor, and transarterial chemoembolization (TACE), were compared to dual therapy consisting of regorafenib and a PD-1 inhibitor in patients with advanced hepatocellular carcinoma (HCC).

Methods: A retrospective analysis was conducted on patients with advanced HCC who underwent second-line therapy from March 2019 to June 2022 at multiple centers. Patients were stratified into two groups: dual therapy (comprising regorafenib and a PD-1 inhibitor) and triple therapy (consisting of regorafenib, a PD-1 inhibitor, and TACE). Propensity score matching (PSM) was used to control for potential confounding variables.

Results: After PSM, 112 eligible patients were included, with 56 in the triple therapy group and 56 in the dual therapy group. Median overall survival (OS) was significantly longer in the triple therapy group (15.4 vs. 8.9 months, p < 0.001), as was median progression-free survival (PFS) (6.8 vs. 3.3 months, p < 0.001). The objective response rate (ORR) (37.5% vs. 5.4%, p < 0.001) and disease control rate (DCR) (73.2% vs. 44.6%, p = 0.002) were significantly higher in the triple therapy group compared to the dual therapy group. The incidence and severity of adverse events were similar between the two groups.

Conclusion: Triple therapy demonstrated superior survival benefits compared to dual therapy in patients with advanced HCC. Additionally, the safety profiles of the two treatment regimens were comparable.

查看原文本刊更多论文

晚期肝细胞癌的瑞戈非尼联合疗法：经导管化疗栓塞与否

简介在晚期肝细胞癌（HCC）患者中，比较了瑞戈非尼、程序性死亡1（PD-1）抑制剂和经动脉化疗栓塞（TACE）三联疗法与瑞戈非尼和PD-1抑制剂二联疗法的有效性和耐受性：对2019年3月至2022年6月期间在多个中心接受二线治疗的晚期HCC患者进行了回顾性分析。患者被分为两组：双联疗法（包括瑞戈非尼和PD-1抑制剂）和三联疗法（包括瑞戈非尼、PD-1抑制剂和TACE）。采用倾向评分匹配法（PSM）控制潜在的混杂变量：经过倾向评分匹配后，共有112名符合条件的患者被纳入治疗方案，其中56人属于三联疗法组，56人属于二联疗法组。三联疗法组的中位总生存期（OS）（15.4 个月对 8.9 个月，P < 0.001）和中位无进展生存期（PFS）（6.8 个月对 3.3 个月，P < 0.001）明显更长。三联疗法组的客观反应率（ORR）（37.5% 对 5.4%，P < 0.001）和疾病控制率（DCR）（73.2% 对 44.6%，P = 0.002）明显高于二联疗法组。两组的不良反应发生率和严重程度相似：结论：在晚期HCC患者中，三联疗法的生存获益优于二联疗法。此外，两种治疗方案的安全性也相当。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology 医学-肿瘤学

CiteScore

6.00

自引率

2.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.